|
1
|
Bandres E, Agirre X, Ramirez N, Zarate R
and Garcia-Foncillas J: MicroRNAs as cancer players: Potential
clinical and biological effects. DNA Cell Biol. 26:273–282. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Deng S, Calin GA, Croce CM, Coukos G and
Zhang L: Mechanisms of microRNA deregulation in human cancer. Cell
Cycle. 7:2643–2646. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ruan K, Fang X and Ouyang G: MicroRNAs:
Novel regulators in the hallmarks of human cancer. Cancer Lett.
285:116–126. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Garg N, Vijayakumar T, Bakhshinyan D,
Venugopal C and Singh SK: MicroRNA regulation of brain tumour
initiating cells in central nervous system tumours. Stem Cells Int.
2015:1417932015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Iorio MV, Ferracin M, Liu CG, Veronese A,
Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M,
et al: MicroRNA gene expression deregulation in human breast
cancer. Cancer Res. 65:7065–7070. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kreth S, Thon N and Kreth FW: Epigenetics
in human gliomas. Cancer Lett. 342:185–192. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hummel R, Maurer J and Haier J: MicroRNAs
in brain tumors: A new diagnostic and therapeutic perspective? Mol
Neurobiol. 44:223–234. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Galani V, Lampri E, Varouktsi A, Alexiou
G, Mitselou A and Kyritsis AP: Genetic and epigenetic alterations
in meningiomas. Clin Neurol Neurosurg. 158:119–125. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Murnyák B, Bognár L, Klekner Á and
Hortobágyi T: Epigenetics of meningiomas. Biomed Res Int.
2015:5324512015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Saydam O, Senol O, Würdinger T, Mizrak A,
Ozdener GB, Stemmer-Rachamimov AO, Yi M, Stephens RM, Krichevsky
AM, Saydam N, et al: miRNA-7 attenuation in Schwannoma tumors
stimulates growth by upregulating three oncogenic signaling
pathways. Cancer Res. 71:852–861. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Catucci I, Yang R, Verderio P, Pizzamiglio
S, Heesen L, Hemminki K, Sutter C, Wappenschmidt B, Dick M, Arnold
N, et al: Evaluation of SNPs in miR-146a, miR-196a2 and miR-499 as
low-penetrance alleles in German and Italian familial breast cancer
cases. Hum Mutat. 31:E1052–E1057. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li P, Shan JX, Chen XH, Zhang D, Su LP,
Huang XY, Yu BQ, Zhi QM, Li CL, Wang YQ, et al: Epigenetic
silencing of microRNA-149 in cancer-associated fibroblasts mediates
prostaglandin E2/interleukin-6 signaling in the tumor
microenvironment. Cell Res. 25:588–603. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu M, Du Y, Gao J, Liu J, Kong X, Gong Y,
Li Z, Wu H and Chen H: Aberrant expression miR-196a is associated
with abnormal apoptosis, invasion, and proliferation of pancreatic
cancer cells. Pancreas. 42:1169–1181. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hu Z, Chen J, Tian T, Zhou X, Gu H, Xu L,
Zeng Y, Miao R, Jin G, Ma H, et al: Genetic variants of miRNA
sequences and non-small cell lung cancer survival. J Clin Invest.
118:2600–2608. 2008.PubMed/NCBI
|
|
15
|
Yazici H, Zipprich J, Peng T, Akisik EZ,
Tigli H, Isin M, Akisik EE, Terry MB, Senie RT, Li L, et al:
Investigation of the miR16-1 (C > T) + 7 substitution in seven
different types of cancer from three ethnic groups. J Oncol.
2009:8275322009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Duan R, Pak C and Jin P: Single nucleotide
polymorphism associated with mature miR-125a alters the processing
of pri-miRNA. Hum Mol Genet. 16:1124–1131. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tian T, Shu Y, Chen J, Hu Z, Xu L, Jin G,
Liang J, Liu P, Zhou X, Miao R, et al: A functional genetic variant
in microRNA-196a2 is associated with increased susceptibility of
lung cancer in Chinese. Cancer Epidemiol Biomarkers Prev.
18:1183–1187. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xu J, Hu Z, Xu Z, Gu H, Yi L, Cao H, Chen
J, Tian T, Liang J, Lin Y, et al: Functional variant in
microRNA-196a2 contributes to the susceptibility of congenital
heart disease in a Chinese population. Hum Mutat. 30:1231–1236.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hu Z, Liang J, Wang Z, Tian T, Zhou X,
Chen J, Miao R, Wang Y, Wang X and Shen H: Common genetic variants
in pre-microRNAs were associated with increased risk of breast
cancer in Chinese women. Hum Mutat. 30:79–84. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Qi P, Dou TH, Geng L, Zhou FG, Gu X, Wang
H and Gao CF: Association of a variant in MIR 196A2 with
susceptibility to hepatocellular carcinoma in male Chinese patients
with chronic hepatitis B virus infection. Hum Immunol. 71:621–626.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Peng S, Kuang Z, Sheng C, Zhang Y, Xu H
and Cheng Q: Association of microRNA-196a-2 gene polymorphism with
gastric cancer risk in a Chinese population. Dig Dis Sci.
55:2288–2293. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang K, Guo H, Hu H, Xiong G, Guan X, Li
J, Xu X, Yang K and Bai Y: A functional variation in
pre-microRNA-196a is associated with susceptibility of esophageal
squamous cell carcinoma risk in Chinese Han. Biomarkers.
15:614–618. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jazdzewski K, Murray EL, Franssila K,
Jarzab B, Schoenberg DR and de la Chapelle A: Common SNP in
pre-miR-146a decreases mature miR expression and predisposes to
papillary thyroid carcinoma. Proc Natl Acad Sci USA. 105:7269–7274.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu Z, Li G, Wei S, Niu J, El-Naggar AK,
Sturgis EM and Wei Q: Genetic variants in selected pre-microRNA
genes and the risk of squamous cell carcinoma of the head and neck.
Cancer. 116:4753–4760. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ahn TK, Kim JO, Kumar H, Choi H, Jo MJ,
Sohn S, Ropper AE, Kim NK and Han IB: Polymorphisms of miR-146a,
miR-149, miR-196a2, and miR-499 are associated with osteoporotic
vertebral compression fractures in Korean postmenopausal women. J
Orthop Res. 36:244–253. 2018.PubMed/NCBI
|
|
26
|
Han M, Yang Q, Feng K, Li R, Ren J and Wei
L: Associations of MMP-2 −1306 C/T and MMP-9 −1562 C/T
polymorphisms with breast cancer risk among different populations:
a meta-analysis. Genes Genom. 39:331–340. 2017. View Article : Google Scholar
|
|
27
|
Benjamini Y and Hochberg Y: Controlling
the false discovery rate: A practical and powerful approach to
multiple testing. J R Stat Soc Series B Stat. 57:289–300. 1995.
|
|
28
|
Kim YR and Hong SH: Influences of
−482C>T and 3238G>C polymorphisms of the apolipoprotein C3
gene on prevalence of metabolic syndrome. Genes Genom. 38:857–864.
2016. View Article : Google Scholar
|
|
29
|
Ritchie MD, Hahn LW, Roodi N, Bailey LR,
Dupont WD, Parl FF and Moore JH: Multifactor-dimensionality
reduction reveals high-order interactions among estrogen-metabolism
genes in sporadic breast cancer. Am J Hum Genet. 69:138–147. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Moore JH and Williams SM: New strategies
for identifying gene-gene interactions in hypertension. Ann Med.
34:88–95. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hahn LW, Ritchie MD and Moore JH:
Multifactor dimensionality reduction software for detecting
gene-gene and gene-environment interactions. Bioinformatics.
19:376–382. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ritchie MD, Hahn LW and Moore JH: Power of
multifactor dimensionality reduction for detecting gene-gene
interactions in the presence of genotyping error, missing data,
phenocopy, and genetic heterogeneity. Genet Epidemiol. 24:150–157.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lee SY, Chung Y, Elston RC, Kim Y and Park
T: Log-linear model-based multifactor dimensionality reduction
method to detect gene gene interactions. Bioinformatics.
23:2589–2595. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jacques G and Cormac O: Central nervous
system tumors. Handb Clin Neurol. 112:931–958. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lacy J, Saadati H and Yu JB: Complications
of brain tumors and their treatment. Hematol Oncol Clin North Am.
26:779–796. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
de Robles P, Fiest KM, Frolkis AD,
Pringsheim T, Atta C, St Germaine-Smith C, Day L, Lam D and Jette
N: The worldwide incidence and prevalence of primary brain tumors:
A systematic review and meta-analysis. Neuro Oncol. 17:776–783.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Choy W, Kim W, Nagasawa D, Stramotas S,
Yew A, Gopen Q, Parsa AT and Yang I: The molecular genetics and
tumor pathogenesis of meningiomas and the future directions of
meningioma treatments. Neurosurg Focus. 30:E62011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Babu R, Sharma R, Bagley JH, Hatef J,
Friedman AH and Adamson C: Vestibular schwannomas in the modern
era: Epidemiology, treatment trends, and disparities in management.
J Neurosurg. 119:121–130. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Huse JT and Aldape KD: The evolving role
of molecular markers in the diagnosis and management of diffuse
glioma. Clin Cancer Res. 20:5601–5611. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Bastien JI, McNeill KA and Fine HA:
Molecular characterizations of glioblastoma, targeted therapy, and
clinical results to date. Cancer. 121:502–516. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Cloughesy TF, Cavenee WK and Mischel PS:
Glioblastoma: From molecular pathology to targeted treatment. Annu
Rev Pathol. 9:1–25. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Louis DN: Molecular pathology of malignant
gliomas. Annu Rev Pathol. 1:97–117. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Liu Y, Pang JC, Dong S, Mao B, Poon WS and
Ng HK: Aberrant CpG island hypermethylation profile is associated
with atypical and anaplastic meningiomas. Hum Pathol. 36:416–425.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Mawrin C and Perry A: Pathological
classification and molecular genetics of meningiomas. J Neurooncol.
99:379–391. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Perry A, Gutmann DH and Reifenberger G:
Molecular pathogenesis of meningiomas. J Neurooncol. 70:183–202.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Yew A, Trang A, Nagasawa DT, Spasic M,
Choy W, Garcia HM and Yang I: Chromosomal alterations, prognostic
factors, and targeted molecular therapies for malignant
meningiomas. J Clin Neurosci. 20:17–22. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Grönholm M, Teesalu T, Tyynelä J, Piltti
K, Böhling T, Wartiovaara K, Vaheri A and Carpén O:
Characterization of the NF2 protein merlin and the ERM protein
ezrin in human, rat, and mouse central nervous system. Mol Cell
Neurosci. 28:683–693. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Giannakakis A, Coukos G, Hatzigeorgiou A,
Sandaltzopoulos R and Zhang L: miRNA genetic alterations in human
cancers. Expert Opin Biol Ther. 7:1375–1386. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Calin GA, Dumitru CD, Shimizu M, Bichi R,
Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, et al:
Frequent deletions and down-regulation of micro-RNA genes miR15 and
miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci
USA. 99:15524–15529. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Guessous F, Alvarado-Velez M,
Marcinkiewicz L, Zhang Y, Kim J, Heister S, Kefas B, Godlewski J,
Schiff D, Purow B and Abounader R: Oncogenic effects of miR-10b in
glioblastoma stem cells. J Neurooncol. 112:153–163. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Shi L, Zhang J, Pan T, Zhou J, Gong W, Liu
N, Fu Z and You Y: MiR-125b is critical for the suppression of
human U251 glioma stem cell proliferation. Brain Res. 1312:120–126.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Alsidawi S, Malek E and Driscoll JJ:
MicroRNAs in brain metastases: Potential role as diagnostics and
therapeutics. Int J Mol Sci. 15:10508–10526. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Besse A, Sana J, Fadrus P and Slaby O:
MicroRNAs involved in chemo- and radioresistance of high-grade
gliomas. Tumour Biol. 34:1969–1978. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Low SY, Ho YK, Too HP, Yap CT and Ng WH:
MicroRNA as potential modulators in chemoresistant high-grade
gliomas. J Clin Neurosci. 21:395–400. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Lv M, Dong W, Li L and Zhang L, Su X, Wang
L, Gao L and Zhang L: Association between genetic variants in
pre-miRNA and colorectal cancer risk in a Chinese population. J
Cancer Res Clin Oncol. 139:1405–1410. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Williams AE, Perry MM, Moschos SA,
Larner-Svensson HM and Lindsay MA: Role of miRNA-146a in the
regulation of the innate immune response and cancer. Biochem Soc
Trans. 36:1211–1215. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Li D, Chen P, Li XY, Zhang LY, Xiong W,
Zhou M, Xiao L, Zeng F, Li XL, Wu MH, et al: Grade-specific
expression profiles of miRNAs/mRNAs and docking study in human
grade I–III astrocytomas. OMICS. 15:673–682. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Pan SJ, Zhan SK, Pei BG, Sun QF, Bian LG
and Sun BM: MicroRNA-149 inhibits proliferation and invasion of
glioma cells via blockade of AKT1 signaling. Int J Immunopathol
Pharmacol. 25:871–881. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Yang G, Han D, Chen X, Zhang D, Wang L,
Shi C, Zhang W, Li C, Chen X, Liu H, et al: MiR-196a exerts its
oncogenic effect in glioblastoma multiforme by inhibition of IκBα
both in vitro and in vivo. Neuro Oncol. 16:652–661. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Guan Y, Chen L, Bao Y, Qiu B, Pang C, Cui
R and Wang Y: High miR-196a and low miR-367 cooperatively correlate
with unfavorable prognosis of high-grade glioma. Int J Clin Exp
Pathol. 8:6576–6588. 2015.PubMed/NCBI
|
